Novocure (NVCR) Tops Q2 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Brazil’s Lula wins historic fourth term, Flavio Bolsonaro refuses to concede
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- Borr Drilling rig sinks off Gabon, one person dead and four missing
- Oil settles lower on peace hopes, Saudi attacks limit losses
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
NovoCure Ltd. (NVCR) PT Raised to $24 at H.C. Wainwright
July 26, 2024 6:48 AM EDTH.C. Wainwright analyst Emily Bodnar raised the price target on NovoCure Ltd. (NASDAQ: NVCR) to $24.00 (from $22.00) while maintaining a Neutral rating.
The analyst comments "Optune growth in glioblastoma (GBM) fueled by impressive France launch; additional launches could occur in 2025. Novocure announced 2Q24 financial results and provided a corporate update on July 25. Sales in 2Q24 were $150.4M, roughly an 8.6% increase from 1Q24. We note that 1Q24 revenues... More



